Older drug for advanced breast cancer beat newer, pricier meds

June 4, 2012 By E.J. Mundell, HealthDay Reporter
Older drug for advanced breast cancer beat newer, pricier meds
Study found Taxol outperformed Abraxane, Ixempra in terms of survival and side effects.

(HealthDay) -- Even in the field of cancer treatment, sometimes newer isn't necessarily better.

That may be the case for patients with advanced breast cancer, who appeared to fare better in a new study when they took an older , Taxol (), instead of two newer and more expensive rivals.

Both of those newer medications, Abraxane and Ixempra, failed to outperform Taxol in terms of either survival without progression of disease or the level of the most noxious side effects, the study of almost 800 found.

"These data suggest that similar patients may be appropriately treated with weekly paclitaxel [Taxol]," said study author Dr. Hope Rugo, director of breast oncology and clinical trials at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco.

She spoke at a news briefing Sunday at the (ASCO) annual meeting in Chicago. The study, which was funded by the U.S. , is to be formally presented on Monday.

Taxol has been used for years to help fight advanced, metastatic breast cancers. But, not every woman fares equally well on Taxol, and newer drugs have emerged, including a variant of paclitaxel called Abraxane (nanoparticle albumin bound paclitaxel) and a drug called Ixempra (ixabepilone).

However, these newer, patented drugs also carry heftier than Taxol, which went off patent years ago. While calculating the exact price difference for any one patient is "enormously complicated," Rugo said that "a like paclitaxel is going to be significantly less expensive than newer agents."

So, are the newer medicines worth the extra money?

In the new study, Rugo and her team tracked outcomes for 799 patients with either locally advanced or metastatic breast cancers. Patients were randomly assigned to received either Taxol, Abraxane or Ixempra weekly, with each cycle involving three weeks of treatment followed by a one-week break. Almost all of the patients in the trial were also receiving the cancer drug Avastin (bevacizumab) at some point, since it was standard therapy at the time. Last fall, the U.S. Food and Drug Administration withdrew its approval of Avastin for the treatment of because of the potential for dangerous cardiac side effects.

Taxol seemed to outperform the newer drugs, Rugo and her team reported. For example, the average time at which women survived without further progression of their cancer was 10.6 months for those taking Taxol, 9.2 months for those on Abraxane and 7.6 months for those taking Ixempra.

Women taking the newer medications also seemed to suffer more side effects. For example, just 16 percent of women taking Taxol experienced the debilitating tingling and numbness of chemotherapy-induced neuropathy, compared to 25 percent of women taking either Abraxane or Ixempra.

Blood-linked toxicities were lowest for women taking Ixempra (12 percent), rose to 21 percent for those on Taxol and climbed to 51 percent for women taking Abraxane, the study found.

Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said the findings "remind us that a hypothesis must always be proven. These randomized trials show us that what is newest and latest is not always best."

So, with this new data, should any woman with metastatic breast cancer receive Abraxane or Ixempra instead of Taxol? Rugo said that most women will probably do fine on , but she noted that a minority typically are allergic to the drug and may prefer to take Abraxane instead.

ASCO spokesman Dr. Nicholas Vogelzang, who moderated the news briefing, said that more is always better when it comes to the number of drugs have on hand.

"All of these agents are clearly active -- I want all three of these on my team when I treat ," said Vogelzang, who is medical director of the developmental therapeutics committee at the Comprehensive Cancer Care Centers of Nevada.

Findings presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

Explore further: Many primary care docs don't know long-term effects of chemo: survey

More information: There's more on the treatment of breast cancer at the American Cancer Society.

Related Stories

Many primary care docs don't know long-term effects of chemo: survey

May 17, 2012
(HealthDay) -- Many primary care doctors don't know the long-term side effects of the chemotherapy treatments that cancer survivors under their care may have been given, a new survey found.

US revokes Roche's Avastin for breast cancer

November 18, 2011
US health officials on Friday revoked the authorization of Roche's Avastin for breast cancer treatment, saying it concluded the drug had "not been shown to be safe and effective for that use."

TGen, Virginia G. Piper Cancer Center studying new breast cancer drug

July 20, 2011
A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation ...

Recommended for you

Scientists discover possible master switch for programming cancer immunotherapy

December 11, 2017
During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells ...

Insights on how SHARPIN promotes cancer progression

December 11, 2017
Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex ...

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

Glioblastoma survival mechanism reveals new therapeutic target

December 11, 2017
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation ...

Liver cancer: Lipid synthesis promotes tumor formation

December 11, 2017
Lipids comprise an optimal energy source and an important cell component. Researchers from the Biozentrum of the University of Basel and from the University of Geneva have now discovered that the protein mTOR stimulates the ...

Use of chemotherapy for early stage breast cancer declines, study says

December 11, 2017
A study of nearly 3,000 women with early stage breast cancer indicates a recent, significant decline in the use of chemotherapy despite the lack of any change in national treatment recommendations or guidelines, according ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.